Adilio Hormigo, MD, PhD, discusses a clinical study on the safety and tolerability of laser interstitial thermal therapy (LITT) and avelumab for recurrent glioblastoma. Glioblastoma is a fatal disease with no standard care for disease progression and is known to evade the immune system. Avelumab is a human IgG1 antibody that binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. Consequently, the suppressive effect on T cell function is inhibited and anti-tumor CD8+ T cell cytotoxicity is restored. LITT is a minimally invasive technique that allows the delivery of light energy, causing disruption of the blood-brain barrier and hyperthermia of a brain lesion, initiating a cascade of events leading to coagulative necrosis and potentially triggering immunogenic death of cancer cells. This clinical trial seeks to determine whether avelumab combined with MRI-guided LITT has acceptable safety and tolerability and will generate robust immunomodulation and clinical activity to treat brain cancer.
Related Presenters
Professor of Neurology, Medicine, and Neurosurgery
Icahn School of Medicine at Mount Sinai
Director of Neuro-Oncology
Mount Sinai Health System
Related Videos
